1-[6-Chloro-4-(trifluoromethyl)pyridin-2-yl]piperazine | 750628-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[6-Chloro-4-(trifluoromethyl)pyridin-2-yl]piperazine
• CAS: 750628-50-3
• 化学式: C₁₀H₁₁ClF₃N₃
• 分子量: 265.666
• InChiKey: RZZSTFZKBKGBKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-[6-Chloro-4-(trifluoromethyl)pyridin-2-yl]piperazine 在 4-二甲氨基吡啶 、 copper(l) iodide 、 potassium carbonate 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 为溶剂， 反应 29.0h， 生成 [3-[4-[4-[6-chloro-4-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]sulfonylphenyl]-2-oxooxazolidin-5-yl]methyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  [EN] PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS
  [FR] COMPOSÉS DE PIPÉRAZINYLSULFONYLARYLE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES

  摘要：

  The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, Y, Q1, Q2, Q3, Q4and Q5are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

  公开号：

  WO2023072794A1
• 作为产物：
  描述：

  哌嗪 、 2,6-二氯-4-三氟甲基吡啶 以 1,4-二氧六环 为溶剂， 以97.6 %的产率得到1-[6-Chloro-4-(trifluoromethyl)pyridin-2-yl]piperazine
  参考文献：
  名称：

  [EN] PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS
  [FR] COMPOSÉS DE PIPÉRAZINYLSULFONYLARYLE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES

  摘要：

  The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, Y, Q1, Q2, Q3, Q4and Q5are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

  公开号：

  WO2023072794A1

文献信息

• The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2
  作者：Pier L. D’Alessandro、Corrado Corti、Adelheid Roth、Annarosa Ugolini、Anna Sava、Dino Montanari、Federica Bianchi、Stephen L. Garland、Ben Powney、Emma L. Koppe、Magalie Rocheville、Greg Osborne、Paloma Perez、Jesús de la Fuente、Maite De Los Frailes、Paul W. Smith、Clive Branch、David Nash、Stephen P. Watson

  DOI：10.1016/j.bmcl.2009.11.032

  日期：2010.1

  The optimisation of an HTS hit series (1) leading to the identification of structurally novel, selective, orally bioavailable mGluR2 positive modulators GSK1331258 and GSK1331268 is described. Structure-activity relationships, attenuation of dopaminergic activity, and potentiation of mGluR2 responses in rat hippocampal MPP-DG synapses are also reported. (C) 2009 Elsevier Ltd. All rights reserved.
• [EN] BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS BENZAMIDE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：[en]F. HOFFMANN-LA ROCHE AG

  公开号：WO2023166103A1

  公开（公告）日：2023-09-07

  The present invention relates to compounds of formula (I), wherein R1to R8, Y, A, Q, X and M are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
• [EN] PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS DE PIPÉRAZINYLSULFONYLARYLE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：[en]F. HOFFMANN-LA ROCHE AG

  公开号：WO2023072794A1

  公开（公告）日：2023-05-04

  The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, Y, Q1, Q2, Q3, Q4and Q5are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.